Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John MacKenzie

Neurology Prescott, AZ Doctor of Osteopathy

NPI 1518078807 CMS profile 294787

1001 Willow Creek Rd Ste 3300, Prescott, AZ 86301

Open in the dashboard

General payments

$6,955

450 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John MacKenzie of Prescott, AZ is reported in the CMS Open Payments database as having received $6,955 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $738 47
2024 General $468 34
2023 General $1,616 96
2022 General $1,896 121
2021 General $859 54
2020 General $197 12
2019 General $1,181 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John MacKenzie
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to John MacKenzie were reported at $738. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year John MacKenzie Neurology median Middle half National median
2019 $1,181 $474 $118–$2,177 $163
2020 $197 $367 $82–$2,309 $114
2021 $859 $438 $104–$2,547 $132
2022 $1,896 $442 $103–$2,388 $149
2023 $1,616 $464 $119–$2,312 $160
2024 $468 $468 $119–$2,323 $164
2025 $738 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,610 110 payments
  2. UCB, Inc. $621 50 payments
  3. ACADIA Pharmaceuticals Inc $414 32 payments
  4. Teva Pharmaceuticals USA, Inc. $397 28 payments
  5. Allergan Inc. $331 27 payments
  6. Medtronic, Inc. $316 14 payments
  7. Novartis Pharmaceuticals Corporation $284 16 payments
  8. Biogen, Inc. $274 15 payments
  9. Alexion Pharmaceuticals, Inc. $248 13 payments
  10. Genentech USA, Inc. $224 13 payments
  11. Other $2,236 132 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,811 439 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $124 10 payments
  3. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $689 44 payments
  2. Briviact $587 47 payments
  3. UBRELVY $564 42 payments
  4. BOTOX Botox Therapeutic $436 31 payments
  5. BOTOX Hyperhydrosis $390 32 payments
  6. NUPLAZID $292 21 payments
  7. SenSight $281 12 payments
  8. AJOVY $204 10 payments
  9. ULTOMIRIS $192 10 payments
  10. ZEPOSIA $174 11 payments
  11. Other $3,655 229 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

3,746

Median for Neurology: 833

Drug cost

$857,380

Median for Neurology: $202,670

Branded share of claims

26.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aubagio Teriflunomide Brand 25 $234,723
Copaxone Glatiramer Acetate Brand 32 $203,811
Nuplazid Pimavanserin Tartrate Brand 15 $74,834
Qulipta Atogepant Brand 27 $37,521
Emgality Pen Galcanezumab-Gnlm Brand 41 $33,280
Ubrelvy Ubrogepant Brand 27 $29,852
Glatopa Glatiramer Acetate Brand 11 $29,568
Vimpat Lacosamide Brand 18 $29,104
Aimovig Autoinjector Erenumab-Aooe Brand 27 $22,862
Oxtellar Xr Oxcarbazepine Brand 19 $19,159

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$319,275

Of which drugs: $211,722

Medicare patients

459

Average age 76

Services billed

44,457

282 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 58%
Ischemic heart disease 32%
Osteoporosis 26%
Depression 25%
Chronic kidney disease 24%
Diabetes 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 72 43,104 $211,723

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $98
$98 27 —
BOTOX
  • AbbVie, Inc. $66
$66 — 43,104
ZEPOSIA
  • Celgene Corporation $43
$43 — —
UBRELVY
  • AbbVie, Inc. $39
$39 27 —
AJOVY
  • Teva Pharmaceuticals USA, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record